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Is it possible to reduce time to appropriate 
treatment of acute coronary syndrome 
through a faster diagnosis?  
Focus on future innovative technologies  
and related treatments
ABSTRACT
Patients with chest pain represent 5% of the total Emergency Department (ED) presentations and among 
these only 5–15% receive a final diagnosis of acute coronary syndrome (ACS), while up to 2% are still 
discharged with a missed ACS diagnosis. The diagnosis of ACS depends on a combination of clinical 
symptoms, ECG findings, and cardiac biomarkers. ACS management starts from the pre-hospital setting, 
where the use of successful networks, efficient emergency medical systems and telemedicine, combined 
with patient education campaigns, has proved to improved survival. Unfortunately, at ED arrival, ACS diag-
nosis still represents a challenge for emergency physicians, whereas clinical presentations can be widely 
variable and the diagnostic tools available are still quite limited. While the 12-lead ECG is the first-line test, 
it could be often non diagnostic so the experimental use of innovative and more accurate device seems 
to overcome its limits. Moreover, the introduction of high-sensitivity or ultrasensitive troponins assays and 
point-of-care (POCT) testing for troponins have proved their utility, reducing the time to rule-in and to rule-out 
for patients presenting with chest pain since ED admission. As soon as ACS is diagnosed, it is mandatory 
to immediately start treatment, according to guidelines. This is even more important in the era of innovative 
and emerging P2Y12 inhibitors that have shown to play an important benefit for ACS treatment. The aim 
of this article is to show the ideal approach to ACS, from symptom onset to early treatment in the ED, to 
show innovative tools for ACS diagnosis and treatment in order to improve outcome for these patients. 
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Introduction
The term ‘acute coronary syndrome’ (ACS) refers to 
any group of clinical symptoms compatible with acute myo-
cardial ischemia and includes unstable angina (UA), non 
ST-segment elevation myocardial infarction (NSTEMI), and 
ST-segment elevation myocardial infarction (STEMI) [1]. 
In the USA, more than 400,000 Americans die 
annually of coronary artery disease, and more than 
1,000,000 have acute coronary syndromes (ACS) [2]. 
Moreover, between 2010 and 2030, the total direct med-
ical costs in the USA for cardiovascular diseases are 
projected to triple from $273 billion to $818 billion [3]; 
consequently there is an urgent need to optimize ACS 
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management with an ideal approach in the early phase 
of the disease in order to reduce myocardium loss and 
to improve patient outcomes worldwide. 
Chest pain patients presenting to the Emergency 
Department (ED) represent 5% of the total number of 
ED accesses. Among these patients, 5–15% receive 
a final diagnosis of ACS, but today still up to 2% are 
discharged with a missed ACS diagnosis [1]. 
The leading symptom that initiates the diagnostic 
and therapeutic cascade for ACS is chest pain, but 
the diagnosis of ACS depends variably on a combina-
tion of clinical symptoms, ECG findings, and cardiac 
biomarkers; classification of patients is based on the 
electrocardiogram (ECG) [1]. 
Management of ACS is targeted at restoring and 
maintaining coronary blood flow and improving myocar-
dial oxygen balance [4]. Early diagnosis and treatment 
in ED is fundamental for improving patient survival. 
Pre-hospital care 
In the first hours from the onset of symptoms the 
possibility of saving lives decreases very quickly with 
time, while the length of the delay to treatment is in-
versely related to the number of saved lives, especially 
in patients with STEMI [5]. Pre-hospital care may be in-
validated by two main causes of delay: ACS symptoms 
late acknowledgment by subject himself and patient’s 
late transport to the hospital. In order to decrease 
these delays it should be important to contemporary 
train patients, EPs and paramedics, and to establish 
a network to improve ambulance response time [6]. The 
main features of a successful network include: a clear 
definition of the geographical areas of interest, target-
ed protocols according to risk stratification, and close 
cooperation among caregivers and institutions [7]. 
It has been demonstrated that these networks induce an 
increase in the number of reperfused patients, a reduc-
tion of heart failure and recurrent myocardial infarction 
and a decrease in both short and long term mortality [8]. 
Patient-related delay is the most difficult to be 
reduced: it is still very long and almost unchanged 
through the years [9]. Patients with longer decision 
times tend to be older, female, diabetics, with atypi-
cal symptoms. Patient education campaigns did not 
yield good results in the past [10], probably because 
of a short duration. Anyway, good results have been 
obtained by AHA Mission Lifeline in the USA [11] and 
by other initiatives in Europe [12, 13]. For example, in 
a randomized controlled trial, Mooney M et al. recent-
ly tested an educational intervention, composed by 
a 40-minutes individualized education session, enforced 
1 month later by telephone call, and they demonstrated 
that median delay time was significantly lower in the 
intervention compared to the control group (1.7 h v. 
7.1 h; p ≤ 0.001) [14]. 
The Emergency Medical System (EMS) plays a key 
role in ACS management: it can receive the call for 
help through an emergency phone number, dispatch 
the proper ambulance and staff to the scene [15], 
rescue the patient, start the pharmacological therapy 
and transport the patient in the fastest way to the most 
suitable centre. Unfortunately, the utilization of the EMS 
in Europe is very variable, ranging from 18 to 85% of the 
STEMI cases in the different countries [16] and it has 
been shown that the lack of the EMS use is linked to 
longer delays in treatment and to worse outcomes [17]. 
There are basically two EMS models: with physi-
cians-staffed ambulances; or with paramedics/nurs-
es-staffed ambulances, working with protocols and phy-
sicians’ support by telemedicine [18, 19]. Telemedicine 
integrates the use of telecommunication and of infor-
mation technologies to eliminate distance barriers and 
facilitate real-time collaborative patient management. 
For example, the use of pre-hospital ECG (PHECG) 
has been shown to reduce the time to reperfusion [20], 
although high quality ECG recording is a specific pro-
cess of care, requiring training [21]. The PHECG can be 
interpreted by the ECG machine automated software, 
by EMS personnel in the ambulance or by a reference 
centre after tele-transmission in order to reduce door-
to-balloon (D2B) time and mortality [22]. The agreement 
on STEMI diagnosis on the ECG between well trained 
paramedics and physicians seems to be good [23], but 
it is important to underline that both knowledge and 
skills should not only be acquired but also maintained 
by physicians and paramedics. However, adherence 
to guidelines and protocols in the pre-hospital setting 
is still suboptimal and widely variable [24]. Regarding 
transport to the ED, there are two main transfer models: 
the hub-and-spoke transfer system [25] and the STEMI 
receiving centre (SRC) organization. In the first model, 
patients presenting directly to a non-PPCI capable cen-
tre are transferred to a PPCI centre, within the shortest 
interval and particularly with the shortest door-in-door-
out time [26]. In the second transfer model, non-SRC 
are bypassed by the transport system, according to 
diversion protocols which allow a direct transfer of the 
patients from the field to a 24 h/7 days PPCI hospital [27]. 
In the experience of the city of Vienna, a partial rotating 
system in the function of SRC among different hospitals 
resulted in an increase of reperfused patients (from 
66 to 87%), in an important reduction of mortality (from 
16.0 to 9.5%), and in an equitable access to care among 
all STEMI patients [13]. Otherwise, a reduction of both 
short and long-term mortality was shown by other net-
works, as the one of Bologna in Italy [28]. 
There is a paucity of evidence-based data in 
pre-hospital ACS care, and high-quality research in 
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this field is mandatory and should be strongly encour-
aged. Chest Pain Clinical Database in the Emergency 
Department is an Italian registry proposal, an observa-
tional prospective study, with the aim to collect data 
about ED patients with chest pain suggestive of ACS. 
These patients differ from those of cardiological trials, 
because they are usually older and they have different 
comorbidities. 
ED arrival: ACS diagnosis
At ED arrival ACS diagnosis needs to be performed 
as soon as possible since a delayed ‘rule in’ increases 
morbidity and mortality, leading to increased risk of 
complications, while delayed ‘rule out’ contributes to 
overcrowding in the ED, increasing patients’ uncertainty 
and anxiety and resulting in a significant cost to the 
healthcare system. 
Typical clinical presentation of ACS patients is 
represented by retrosternal pressure or heaviness 
(‘angina’) radiating to the left arm, neck, or jaw, which 
may be intermittent (usually lasting for several minutes) 
or persistent. Other common presentation symptoms 
are diaphoresis, nausea, abdominal pain, dyspnea, and 
syncope. However, 30% of STEMI patients arrive at ED 
presenting atypical symptoms [29] such as epigastric 
pain, indigestion, stabbing chest pain, chest pain with 
some pleuritic features, or increasing dyspnea (often 
observed in elderly patients, in women, and in patients 
with diabetes, chronic renal failure, or dementia). 
Moreover, the exacerbation of symptoms by physical 
exertion, or their relief at rest or after the administra-
tion of nitrates, supports a diagnosis of ischemia [7]. 
However, EPs well know that ACS patients may be total-
ly asymptomatic and that chest pain can be a confusing 
symptom, and it can hide other life-threatening diseas-
es, apart from ACS, such as pulmonary embolism, aortic 
dissection, pericarditis, valvular heart disease [30]. 
ECG
A 12-lead electrocardiogram (ECG) is the single, 
first-line, most important test in the initial evaluation 
of patients with ACS, and it should be obtained within 
10 minutes from the first medical contact [31]. ECG 
recordings should be repeated at least at 3 h, 6–9 h and 
24 h after first presentation, and immediately in the case 
of recurrence of chest pain or symptoms [7]. However, it 
is well known that 12-lead ECG is often non diagnostic. 
Moreover, it should be remembered that the posterior 
and lateral walls are not adequately represented on the 
12-lead ECG and therefore it may not completely ex-
clude ischemia in those territories. These considerations 
lead to the introduction of a new, more accurate ECG 
device with 80 Leads ECG (Heartscape). This system 
utilizes 80 data collection points, including 58 anterior 
leads, 12 lateral leads, and 10 posterior leads, that 
provide a 360-degree view of the electrical activity of 
the heart. The increased spatial view of the heart can 
assist EPs to better diagnose chest pain patients in the 
ED. The device is easy-to-use and directly shows on 
the monitor a 3D Colour-coded Torso Map, built using 
data from a single beat taken at each electrode. Red 
colour represents a positive deflection above isoelec-
tric, blue colour a negative deflection below isoelec-
tric, while green colour means no deflection (Fig. 1). 
Figure 1. 80-lead 3D ECG System
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The OCCULT-MI trial [32] showed the incremental bene-
fit of Heartscape in detecting ACS in patients without ST- 
-elevation myocardial infarction, compared to traditional 
12-lead ECG. The sensitivity of the 80L for ACS had 
a relative increase of 73% and an actual increase of 5.2% 
(p = 0.0025). The absolute reduction in specificity was 
less than 3%, not clinically significant [32]. 
Troponins
The second pivotal tool to achieve ACS diagnosis 
includes cardiac troponin measurement, indifferently 
T or I troponin [33, 34]. Elevation of cardiac troponins 
reflects myocardial cellular damage [35]. Troponin 
increase occurs within 4 h after symptom onset and it 
may remain elevated for up to 2 weeks. The diagnostic 
cut-off exceeds the 99th percentile of a normal reference 
population [36]. However, troponin evaluation requires 
long time to make ACS diagnosis, thus contributing to 
ED overcrowding and patients’ anxiety. Thus, the recent 
introduction of high-sensitivity or ultrasensitive assays, 
that have a 10- to 100-fold lower limit of detection, has 
already shown its utility in the ED [37, 38]. The negative 
predictive value with a high-sensitivity or ultrasensitive 
troponin single test on admission is > 95% and it im-
proves to 100% with the second sample within 3 h [39, 40]. 
Even though other clinical conditions, apart from ACS, 
may lead to troponin elevation, it is important to remem-
ber that any increase of troponin value is associated 
with worse prognosis [41–43]. 
Where central laboratory requires too much time to 
measure troponin level, point-of-care (POC) tests for 
troponins allow to save about 1 h of wasted time [44] 
and to rapidly rule-out low risk group within 2 h [45] 
However, POC tests showed to have worse analytic 
reliability and poor sensitivity, compared to central 
laboratory tests. The ASPECT study showed that only 
9.8% of 3.582 patients with suspected ACS could be 
safely discharged 2 h after presentation, using POC 
troponin test [46]. This finding suggests that POC 
troponin tests application could be more useful for 
patient’s disposition than for ACS diagnosis: if the 
rapid POC test is positive, hospitalization is needed, 
while if the POC test is negative (as occurs in nearly 
90% of patients), the patient may be admitted to the 
chest pain unit (CPU) to continue his serial testing 
with the higher sensitivity central laboratory troponin 
test [47]. Compared to central laboratory troponin, the 
use of POC tests has already proved to be very useful 
in shortening ED stay [48]. However, its use is still 
limited and further researches are needed to confirm 
preliminary results and to standardize its application 
in the ED [48]. 
ACS treatment in ED
As soon as ACS is diagnosed, it is mandatory to start 
treatment immediately in the ED, according to ESC guide-
lines [7, 49], to which we refer for better insights (Fig. 2). 
The first approach includes the use of an initial dose 
of 150–500 mg orally or 250 mg i.v. of aspirin [7, 49] 
and a loading dose of a P2Y12 inhibitor. The PLATO 
study and the TRITON study provided evidence that 
the more potent effect of ticagrelor as well as prasugrel 
on P2Y12 inhibition results in a significant reduction of 
athero-thrombotic events as compared to clopidogrel 
in patients with ACS [50, 51]. Ticagrelor is indicated in 
all-comers, prasugrel only prior PCI in patients without 
prior stroke/TIA whose anatomy is known, clopidogrel 
if ticagrelor and prasugrel are not available [47, 52]. 
While clopidogrel and prasugrel need to form the 
active metabolites in the liver [53, 54], ticagrelor and 
Figure 2. ACS management
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new P2Y12 inhibitors, such as cangrelor and elinogrel, 
are direct, reversible antagonists [55–57]. There are 
several limitations of P2Y12 orally administered inhibi-
tors especially if used in patients with ACS treated with 
PCI [58– 60]. Oral P2Y12 inhibitors cannot provide 
reliable inhibition in patients who are unable to swal-
low or rapidly absorb medication taken orally such 
as patients who are sedated, intubated, in shock, or 
those with nausea or vomiting [61, 62]. Cangrelor has 
the advantage over all orally administered agents of 
being a very potent, quickly reversible and direct-act-
ing P2Y12 antagonist reaching consistent optimal 
platelet inhibition within minutes after the start of the 
infusion [60, 63]. Cangrelor does not require hepat-
ic activation [64]. The drug is rapidly metabolized 
through dephosphorylation by an endonucleotidase 
located on the surface of vascular endothelial cells 
with an elimination half-life of 2.9 to 5.5 min [65, 66]. 
Lack of interaction between cangrelor and ticagrelor 
may suggest choosing the last one for maintenance 
treatment if cangrelor was used in the acute setting, 
but this should be clinically tested. Cangrelor was not 
superior to clopidogrel in reducing the incidence of 
ischemic events in neither of the CHAMPION trials: 
CHAMPION PLATFORM [67] and CHAMPION PCI [68]. 
On the other hand, CHAMPION PHOENIX trial showed 
that the primary composite efficacy end point of death 
from any cause was significantly lower in the cangrelor 
group than in the clopidogrel group, not accompanied 
by a significant increase in severe bleeding or in the 
need for transfusions as compared to patients on 
clopidogrel [69]. Moreover, only 1 h is required in 
patients treated with cangrelor to return to baseline 
platelet function. Unfortunately, cangrelor is not avail-
able yet, however its pharmacodynamic properties 
(prompt and potent onset of action and fast offset) 
make it a desirable drug in the emergency setting. 
Another masterpiece of ACS treatment is anti-
coagulation and different strategies are available: 
fondaparinux 2.5 mg/daily subcutaneously, that has the 
best benefit/risk profile, enoxaparin 1 mg/kg twice daily 
subcutaneously for low bleeding risk patients, UFH i.v. 
bolus 60–70 IU/kg (maximum 5000 IU) followed by in-
fusion of 12–15 IU/kg/h (maximum 1000 IU/h) titrated to 
aPTT 1.5–2.5 × control [7, 49], or bivalirudin, indicated 
only in patients with a planned invasive strategy [70]. 
Glycoprotein IIb/IIIa  is recommended only in high 
risk PCI patients, particularly in those not treated with 
P2Y12 inhibitors [71]. Furthermore, nitrates (oral or 
intravenous) are usually administered to relieve angina, 
especially in patients with hypertension or heart failure 
but they are contraindicated in case of hypotension, 
right ventricular infarction or use of phosphodiesterase 
type 5 inhibitors in the previous 48 h [49]. In addition, 
beta-blockers are indicated in patients with tachycar-
dia, hypertension, and/or left ventricular dysfunction, 
while non-dihydropyridine calcium channel blocker 
may be considered in patients without heart failure 
already treated with beta-blockers or with contraindi-
cation to beta-blockers. In STEMI patients primary PCI 
is recommended within 120 min [49, 72], otherwise 
fibrinolytic therapy is indicated within 12 h of symp-
tom onset in patients without contraindications [73]. 
Approximately 10–25% of patients with ACS eventually 
require non-invasive ventilator support for acute respi-
ratory failure secondary to acute pulmonary edema, 
cardiogenic shock or cardiac arrest. Two randomized 
trials from Japan have analyzed the effect of continu-
ous positive airway pressure (CPAP) in patients with 
AMI [74, 75], showing a reduction in the endotracheal 
intubation rate and faster improvement in acute re-
spiratory failure. However, no study has specifically 
evaluated the usefulness of bilevel pressure support 
ventilation (NIPSV) compared to conventional oxygen 
therapy yet, but a possible adverse effect of the higher 
positive intrathoracic pressure generated by bilevel 
NIPSV, leading to hypotension and a decrease in 
coronary blood flow, was suggested [76]. A recent 
retrospective series of 206 patients has shown that pa-
tients with AMI treated with non-invasive ventilation (NIV) 
tended to have a higher mortality rate, confirming the 
evidence that the prognosis depends primarily on the 
severity of the myocardial injury rather than the degree 
of acute respiratory failure [77]. Unfortunately, most of 
the series of patients with AMI and NIV are retrospec-
tive and do not analyze ventilator parameters in detail. 
In accordance with previous data, mortality risk is better 
predicted by co-morbidities than by respiratory or direct 
cardiac parameters. NIV could be an independent risk 
factor of mid-term mortality [78]. It is likely that com-
plications related to NIV, mainly ventilator-associated 
pneumonia, may explain these findings. 
Conclusions
A fast diagnosis for patients with ACS is a chal-
lenging issue in order to start appropriate treatment. 
Innovative, accurate, rapid and easy-to-use tools are 
emerging to solve this problem. Pre-hospital care, 
ED arrival, and ACS treatment should be considered 
a continuum of the same rapid, accurate and effective 
ACS management. A shared protocol between EP 
physicians and cardiologists together with the use of 
innovative diagnostic approach, such as high sensitive 
ECG and troponin assessment, could lead to a shorter 
time to diagnosis and therapeutic strategies resulting 
in better outcome for these patients. 
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